European Archives - Page 845 of 984 - European Medical Journal

EMJ

Laser Ablation: A Low-Risk, Highly Effective Option for Prostate Cancer Patients

NEW, less invasive therapy has been discovered for the treatment of prostate cancer. The therapy provides a middle ground for men who have previously had…

EMJ

Risk Warning for Higher Salt Consumption in CKD Patients

HIGH salt intake could lead to an increased risk of cardiovascular disease (CVD) among chronic kidney disease (CKD) patients, according to a recent study…

EMJ Interventional Cardiology 4 [Suppl 12] 2016

Bioresorbable vascular scaffold (BRS/bioabsorbable stents are a new and promising generation of intravascular devices that may potentially circumvent…

Bioresorbable Vascular Scaffolds as Optimal Treatment for Selected Patients in our Clinical Practice

Bioresorbable vascular scaffolds (BRS)/bioabsorbable stents are a new and promising generation of intravascular devices that may potentially circumvent…

New Data Show Sandoz Biosimilar Etanercept Candidate Has Equivalent Efficacy to Originator Product

Holzkirchen, July 7, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial…

Merck Commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17

Darmstadt, Germany, July 06, 2016 – Merck, a leading science and technology company, today announced it would continue to support the advancement of…

Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance

Darmstadt, Germany, June 30, 2016 – Merck, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and…

Introducing EMJ Nephrology 4.1

United Kingdom, July 5, 2016: Welcome to the 2016 edition of EMJ Nephrology, which provides extensive coverage of research and developments across the…

EMJ

Best Award Winners at ERA-EDTA 2016

The ERA-EDTA recognised a selection of authors for what the organisation deemed to be the best presentations of research abstracts at the congress.

Anti-Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly over Placebo

Barcelona-Lugano, July 02, 2016 – A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and…